Daniel Emerling Selected Research

1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)

9/2016

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Daniel Emerling Research Topics

Disease

5	Malaria 01/2022 - 09/2016
2	Granulomatosis with Polyangiitis (Wegener's Granulomatosis) 01/2023 - 01/2019
2	Infections 11/2017 - 09/2016
1	Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis 01/2023
1	Autoimmune Diseases (Autoimmune Disease) 01/2023
1	Vasculitis (Vasculitides) 01/2023
1	Parasitic Diseases (Parasitic Disease) 09/2016
1	Rheumatoid Arthritis 01/2013

Drug/Important Bio-Agent (IBA)

4	VaccinesIBA 01/2022 - 09/2016
2	Myeloblastin (Proteinase 3)IBA 01/2023 - 01/2019
2	AntigensIBA 01/2023 - 11/2017
2	Antineutrophil Cytoplasmic Antibodies (ANCA)IBA 01/2023 - 01/2019
1	EpitopesIBA 01/2023
1	AutoantigensIBA 01/2019
1	Monoclonal AntibodiesIBA 11/2017
1	Plasmodium falciparum Pfs25 proteinIBA 11/2017
1	1- acetyl- 1,2,3,3a,8,8a- hexahydro- 8a- hydroxy- 5- methoxypyrrolo(2,3- b)indole (CHMI)IBA 09/2016
1	Malaria VaccinesIBA 09/2016
1	3-benzoyl dopamine (MBDA)IBA 01/2013
1	Biomarkers (Surrogate Marker)IBA 01/2013

Therapy/Procedure

1	Therapeutics 01/2013